Skip to main content

APROXIMACION MULTIOMICA PARA IDENTIFICAR BIOMARCADORES PREDICTIVOS Y REVERTIR MECANISMOS DE RESISTENCIA A OSIMERTINIB EN CANCER DE PULMON CON MUTACION DE EGFR

PID2022-137965OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA INVESTIGACION HOSPITAL UNIVERSITARIO LA FE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1

  • Exposito, Francisco
  • Redrado, Miriam
  • Serrano, Diego
  • Calabuig-Fariñas, Silvia
  • Bao-Caamano, Aida
  • Gallach-Garcia, Sandra
  • Díaz-Lagares, Ángel
  • Rodriguez-Casanova, Aitor
  • Sandoval, Juan
  • San Jose-Eneriz, Edurne
  • Garcia, Javier
  • Redin, Esther
  • Senent, Yaiza
  • Leon, Sergio
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] The treatment of non-small cell lung cancer (NSCLC) patients has significantly improved with recent therapeutic strategies; however, many patients still do not benefit from them. As a result, new treatment approaches are urgently needed. In this study, we evaluated the antitumor efficacy of co-targeting G9a and DNMT1 enzymes and its potential as a cancer drug sensitizer. We observed co-expression and overexpression of G9a and DNMT1 in NSCLC, which were associated with poor prognosis. Co-targeting G9a/DNMT1 with the drug CM-272 reduced proliferation and induced cell death in a panel of human and murine NSCLC cell lines. Additionally, the transcriptomes of these cells were reprogrammed to become highly responsive to chemotherapy (cisplatin), targeted therapy (trametinib), and epigenetic therapy (vorinostat). In vivo, CM-272 reduced tumor volume in human and murine cell-derived cancer models, and this effect was synergistically enhanced by cisplatin. The expression of SCARA5 and AOX1 was induced by CM-272, and both proteins were found to be essential for the antiproliferative response, as gene silencing decreased cytotoxicity. Furthermore, the expression of SCARA5 and AOX1 was positively correlated with each other and inversely correlated with G9a and DNMT1 expression in NSCLC patients. SCARA5 and AOX1 DNA promoters were hypermethylated in NSCLC, and SCARA5 methylation was identified as an epigenetic biomarker in tumors and liquid biopsies from NSCLC patients. Thus, we demonstrate that co-targeting G9a/DNMT1 is a promising strategy to enhance the efficacy of cancer drugs, and SCARA5 methylation could serve as a non-invasive biomarker to monitor tumor progression., This work has been funded by: FIMA, ISCIII-Fondo de Investigacion Sanitaria-FondoEuropeo de Desarrollo Regional 'Una manera de hacer Europa' (PI22/01253 to AC, PI22/0451 to LMM, CIBERONC CB16/12/00443 to LMM, CB16/12/00486 to FP, CB16/12/00350 to EJL), MICIN PID2022-137965OB-I00 to JS. Fellowship support: FE, Asociacion de Amigos de la Universidad de Navarra" in association with "La Caixa" Banking Foundation; DS, Juan de la Cierva-Incorporacion.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Genome-wide methylation analysis of circulating cell-free DNA identifies an episignature in lung cancer: validation of EMP2 as a potential biomarker

  • Alemany-Cosme, Ester
  • Cruz-Chamorro, Dario
  • Garcia, Diana
  • Martinez-Tomas, Raquel
  • Briones-Gomez, Andres
  • Galbis-Caravajal, Jose
  • Calvo, Alfonso
  • Juan, Oscar
  • Lahoz, Agustin
  • Cases, Enrique
  • Palanca-Ballester, Cora
  • Sandoval, Juan
  • Hervás-Marín, David|||0000-0003-0635-4961
[EN] Background: Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. Its poor prognosis is largely attributed to late-stage diagnosis, highlighting the need for sensitive, minimally invasive biomarkers for early detection. In this study, we aimed to identify circulating cell-free DNA (cfDNA) methylation-based biomarkers for LC through genome-wide profiling of plasma-derived cfDNA from patients with LC (stages I-IV) using the Infinium DNA MethylationEPIC array (> 850,000 CpGs). A relaxed elastic net penalized logistic regression model was applied to identify differentially methylated CpGs between LC patients and non-neoplastic controls, and selected candidates were validated in an independent cohort. Results: A 21-CpG episignature was identified, predominantly hypomethylated in LC, which distinguished cases (n = 25) from controls (n = 8) with a cross-validated area under the curve (AUC) of 0.70. Two CpGs with the largest effect sizes (associated with EMP2 and IKZF2) were selected for validation. Digital droplet PCR (ddPCR) analysis in an independent cohort of 47 individuals (23 LC patients and 24 controls) confirmed significant hypomethylation at the EMP2 locus (median % methylation: 73.60% in tumors vs. 86.83% in controls; p = 0.0034), achieving an AUC of 0.75. Conclusions: Our findings support the utility of methylome-wide cfDNA profiling for LC biomarker discovery. EMP2 promoter methylation represents a promising candidate for the minimally invasive detection of LC across heterogeneous clinical presentations., This work was supported by the ISCIII ("PI19/00572"), co-funded by ERDF/ESF, "A way to make Europe"/"Investing in your future", Proyectos de Generacion de Conocimiento 2022 Proyecto PID2022-137965OB-I00 from MCIN/ AEI /https://doi.org/10.13039/501100011033/ and FEDER "A way to make Europe" and the Conselleria de innovacion, universidades, ciencia y sociedad digital (CIAICO/2022/251). E. Alemany-Cosme was supported by a grant of ISCIII (FI20/00136), D. Cruz-Chamorro and C Palanca-Ballester were supported by Grants from Generalitat Valenciana (CIAPOT/2022/21 and FDEGENT/2019/014), respectively.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Reduced Levels of miR-145-3p Drive Cell Cycle Progression in Advanced High-Grade Serous Ovarian Cancer

  • González-Cantó, Eva
  • Monteiro, Mariana
  • Aghababyan, Cristina
  • Ferrero-Micó, Ana
  • Navarro-Serna, Sergio
  • Mellado-López, Maravillas
  • Tomás-Pérez, Sarai
  • Sandoval, Juan
  • Llueca, Antoni
  • Herreros-Pomares, Alejandro
  • Gilabert-Estellés, Juan
  • Pérez-García, Vicente
  • Marí-Alexandre, Josep
High-grade serous ovarian cancer (HGSOC) is the most lethal form of gynecologic cancer, with limited treatment options and a poor prognosis. Epigenetic factors, such as microRNAs (miRNAs) and DNA methylation, play pivotal roles in cancer progression, yet their specific contributions to HGSOC remain insufficiently understood. In this study, we performed comprehensive high-throughput analyses to identify dysregulated miRNAs in HGSOC and investigate their epigenetic regulation. Analysis of tissue samples from advanced-stage HGSOC patients revealed 20 differentially expressed miRNAs, 11 of which were corroborated via RT-qPCR in patient samples and cancer cell lines. Among these, miR-145-3p was consistently downregulated post-neoadjuvant therapy and was able to distinguish tumoural from control tissues. Further investigation confirmed that DNA methylation controls MIR145 expression. Functional assays showed that overexpression of miR-145-3p significantly reduced cell migration and induced G0/G1 cell cycle arrest by modulating the cyclin D1-CDK4/6 pathway. These findings suggest that miR-145-3p downregulation enhances cell proliferation and motility in HGSOC, implicating its restoration as a potential therapeutic target focused on G1/S phase regulation in the treatment of HGSOC., This research was funded by the “Instituto de Salud Carlos III Fondo Europeo de Desarrollo Regional” (ISCIII-FEDER), Spain (PI17/01945 and PI22/01872), the “Generalitat Valenciana”, Spain (GV/2020/200), the “Sociedad de Obstetricia y Ginecología de la Comunidad Valenciana” (SOGCV), Spain (Prize SOGCV 2019), the “Fundación para la Investigación del Hospital General Universitario de Valencia” (FIHGUV), Spain (Prize FIHGUV 2019 and 2023), and Amunt Contra el Càncer (patients’ non-profit association; Denia, Spain). E.G.-C. is supported by a pre-doctoral grant from the “Generalitat Valenciana” (ACIF/2020/216); A.F.-M. and S.T.-P. are supported by pre-doctoral grants from the “Junta Asociada Provincial de Valencia de la Asociación Española Contra el Cáncer (AECC)”; J.S. is supported by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (PID2022-137965OB-I00); V.P.-G. is supported by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación MICIU/AEI/10.13039/501100011033, and by ESF investing in your future (CNS2022-135933, PID2020-114459RA-I00 and PLEC2022-009246) and Fundación Ramón Areces., Peer reviewed